
Origami Therapeutics, Inc.
Origami Therapeutics, Inc. is a YC Winter 2022 (W22) company. Based in San Diego, CA, USA. Team of 4.
About Origami Therapeutics, Inc.
Summary
Origami Therapeutics, Inc. develops oral small-molecule protein degraders that clear toxic proteins from the brain to slow or stop neurodegeneration. Its lead program targets Huntington's disease, where a mutant protein drives progressive, fatal nerve cell death. The company uses proprietary human disease neuron models to screen candidates, replacing earlier-stage discovery work that relied on less clinically predictive model systems.
From the Y Combinator listing
Oral drugs to halt neurodegeneration
Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best chance of clinical success. Our first indication is Huntington’s disease, a debilitating, progressive and ultimately fatal disorder caused by a genetic mutation. We have already identified small molecules that reduce the toxic mutated protein, suppress mutant protein-induced toxicities in human disease neurons and get into the brain. We anticipate that this approach will be broadly applicable to traditionally “undruggable” targets in other neurological diseases.
Facts
- Healthcare / Healthcare -> Therapeutics
- San Diego, CA, USA
- 4
- Active
- Early
Founders (1)
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works